Published in Clin Cancer Res on November 15, 2008
The role of HDAC6 in cancer. J Biomed Biotechnol (2010) 1.77
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell (2013) 1.69
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A (2010) 1.62
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer (2014) 1.52
Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A (2009) 1.46
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14
HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia (2011) 1.11
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest (2013) 0.99
Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One (2011) 0.96
Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem (2013) 0.95
Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLoS One (2012) 0.94
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol Cancer Ther (2010) 0.93
Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res (2014) 0.93
Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol (2009) 0.92
Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells. Oncotarget (2015) 0.90
Involvement of autophagy in ovarian cancer: a working hypothesis. J Ovarian Res (2012) 0.89
Dido3-dependent HDAC6 targeting controls cilium size. Nat Commun (2014) 0.88
Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One (2011) 0.87
The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg Med Chem Lett (2011) 0.85
HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion. PLoS One (2013) 0.84
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol Ther (2014) 0.81
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process. Cancer Biol Ther (2014) 0.80
ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol (2017) 0.79
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochem Pharmacol (2016) 0.77
USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment. Oncotarget (2016) 0.77
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. Mol Oncol (2016) 0.76
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Oncotarget (2016) 0.75
Ubiquitin pathway and ovarian cancer. Curr Oncol (2012) 0.75
Advances in epigenetic glioblastoma therapy. Oncotarget (2017) 0.75
HDAC6 and ovarian cancer. Int J Mol Sci (2013) 0.75
The role of prostate tumor overexpressed 1 in cancer progression. Oncotarget (2016) 0.75
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma. J Ovarian Res (2017) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
HDAC6 is a microtubule-associated deacetylase. Nature (2002) 12.76
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature (2007) 7.74
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell (2003) 7.71
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A (1994) 6.74
HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem (2005) 5.89
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A (2003) 5.56
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev (2007) 2.56
Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol (2007) 2.25
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci (2007) 2.22
Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ (2005) 2.21
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc Natl Acad Sci U S A (2002) 1.89
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene (2005) 1.79
Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res (2008) 1.64
HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy (2007) 1.62
Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc (2003) 1.48
Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett (2001) 1.44
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41
The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene (2004) 1.34
Proteasome inhibition in the treatment of cancer. Cell Cycle (2005) 1.32
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol (2006) 1.29
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J Med Chem (2007) 1.22
P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow. Clin Chem (2007) 1.04
Clinical update: novel targets in gynecologic malignancies. Semin Oncol (2004) 0.86
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron (2010) 4.76
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Chemical phylogenetics of histone deacetylases. Nat Chem Biol (2010) 4.36
Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science (2009) 3.47
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron (2008) 2.88
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci (2006) 2.85
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Bioorthogonal turn-on probes for imaging small molecules inside living cells. Angew Chem Int Ed Engl (2010) 2.57
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet (2007) 2.44
Is the easier way ever the better way? J Clin Oncol (2011) 2.41
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci (2012) 2.35
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Longitudinal care improves disclosure of psychosocial information. Arch Pediatr Adolesc Med (2003) 2.29
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci (2007) 2.22
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem (2008) 2.12
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet (2004) 2.02
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol (2009) 1.99
Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci (2012) 1.95
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Joint Modeling and Estimation for Recurrent Event Processes and Failure Time Data. J Am Stat Assoc (2004) 1.87
Effects of improved access to safety counseling, products, and home visits on parents' safety practices: results of a randomized trial. Arch Pediatr Adolesc Med (2002) 1.83
Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol (2011) 1.82
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol (2005) 1.81
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci (2005) 1.75
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma (2011) 1.59
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci (2009) 1.55
A robust small-molecule microarray platform for screening cell lysates. Chem Biol (2006) 1.52
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Using a computer kiosk to promote child safety: results of a randomized, controlled trial in an urban pediatric emergency department. Pediatrics (2007) 1.48
Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol (2002) 1.46
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol (2012) 1.46
Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci (2008) 1.44
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging (2004) 1.44
Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol (2010) 1.44
Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer (2009) 1.44
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. J Med Chem (2009) 1.42
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41
Improving child and parent mental health in primary care: a cluster-randomized trial of communication skills training. Pediatrics (2008) 1.39
Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol (2012) 1.38
Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol (2007) 1.35
Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem (2008) 1.34
A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol (2007) 1.31
Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J Neurosci (2004) 1.31
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res (2006) 1.28
Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A (2008) 1.27
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27
Analysing panel count data with informative observation times. Biometrika (2006) 1.27
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol (2012) 1.26
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26
Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagn Pathol (2012) 1.25
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep (2012) 1.24
Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol (2010) 1.23
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol (2013) 1.23
Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer (2007) 1.22
Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res (2009) 1.22
Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics (2003) 1.20
DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer (2013) 1.20
Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol (2006) 1.20
Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer (2010) 1.20
Synapse microarray identification of small molecules that enhance synaptogenesis. Nat Commun (2011) 1.19
Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg (2010) 1.19
On the inhibition of histone deacetylase 8. Bioorg Med Chem (2010) 1.18
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol (2009) 1.18